Last reviewed · How we verify

TNF Inhibitor (W12-W48) — Competitive Intelligence Brief

TNF Inhibitor (W12-W48) (TNF Inhibitor (W12-W48)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor. Area: Immunology.

phase 3 TNF inhibitor TNF (tumor necrosis factor) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

TNF Inhibitor (W12-W48) (TNF Inhibitor (W12-W48)) — University Hospital, Montpellier. TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce systemic inflammation and immune-mediated tissue damage.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TNF Inhibitor (W12-W48) TARGET TNF Inhibitor (W12-W48) University Hospital, Montpellier phase 3 TNF inhibitor TNF (tumor necrosis factor)
Etanercept + Methotrexate Etanercept + Methotrexate Wyeth is now a wholly owned subsidiary of Pfizer marketed TNF inhibitor + DMARD combination TNF-alpha receptor (etanercept); dihydrofolate reductase (methotrexate)
ETN+MTX ETN+MTX Japan Biological Agent Study Integrated Consortium marketed TNF inhibitor + DMARD combination TNF-α receptor; dihydrofolate reductase
Etanercept (ETN) Etanercept (ETN) University of Leeds marketed TNF inhibitor (TNF receptor fusion protein) TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
Tapered doses of TNFi Tapered doses of TNFi University Health Network, Toronto marketed TNF inhibitor (tapered dosing strategy) TNF-alpha
etanercept (EnbrelTM) etanercept (EnbrelTM) Wyeth is now a wholly owned subsidiary of Pfizer marketed TNF receptor antagonist (TNF inhibitor) TNF-α and TNF-β (tumor necrosis factor)
Etanercept + Acitretin Etanercept + Acitretin Pfizer marketed TNF inhibitor + retinoid combination TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor class)

  1. University Hospital, Montpellier · 2 drugs in this class
  2. Amgen · 1 drug in this class
  3. Biogen · 1 drug in this class
  4. Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
  5. National Eye Institute (NEI) · 1 drug in this class
  6. Abbott · 1 drug in this class
  7. Spanish Clinical Pharmacology Society · 1 drug in this class
  8. Takeda · 1 drug in this class
  9. University Health Network, Toronto · 1 drug in this class
  10. University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TNF Inhibitor (W12-W48) — Competitive Intelligence Brief. https://druglandscape.com/ci/tnf-inhibitor-w12-w48. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: